Introduction: Obesity and diabetes are known risk factors for endometrial cancer; thus, the genetic risk factors of these phenotypes might also be associated with endometrial cancer risk. To evaluate this hypothesis, we genotyped tag-single nucleotide polymorphisms (SNP) and candidate SNPs in FTO and HHEX in a primary set of 417 endometrial cancer cases and 406 population-based controls, and validated significant findings in a replication set of approximately 2,347 cases and 3,140 controls from three additional studies.
Introduction
Obesity and type II diabetes are major risk factors for endometrial cancer. Genetic variation that is associated with obesity and diabetes might provide clues to the molecular pathways mediating endometrial carcinogenesis. A genome-wide association study of body mass index (BMI) identified a 47 kb region on chromosome 16 encompassing the FTO gene intron 1-exon 2-intron 2 that is marked by tag-single nucleotide polymorphisms (SNP) rs8050136 (and the correlated SNP rs9939609; r 2 = 1) to be associated with BMI (1) . Another genome-wide association study of type II diabetes (2) identified the HHEX gene region on chromosome 10 marked by rs1111875 that is also associated with BMI. To examine whether genetic variants of FTO and HHEX are associated with endometrial cancer risk, we genotyped tagSNPs and candidate SNPs in the Polish Endometrial Case-Control Study (PECS) of 417 endometrial cancer cases and 406 population-based controls (3). Significant findings in this set were then selected for validation in a replication set of approximately 2,347 cases and 3,140 controls from three additional studies.
PECS Methods
Genotyping of 189 tagSNPs in FTO (including rs8050136) and 5 tagSNPs in HHEX (including rs1111875) were done as part of an Illumina Infinium custom iSelect chip using a SNP selection strategy described previously (4) . For FTO, four SNPs were excluded due to violations of quality control measures: concordance of 1% replicates, completion proportions, and departure from Hardy-Weinberg proportions (P < 0.05). An additional 14 SNPs were excluded due to minor allele frequencies (MAF) of <0.05 among controls. For HHEX, all five SNPs passed quality control filters. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to estimate the association between SNPs and endometrial cancer risk using unconditional logistic regression models, controlling for matching factors, age, and study site. We also conducted analyses of haplotypes, including the sequential haplotype scan (5) and the variable-sized sliding window-regularized regression association analysis (6) to localize a set of adjacent markers associated with risk. Due to the size of the FTO gene, the sequential haplotype scan was performed in three overlapping sections [section 1 (SNPs 1-65), rs8055834-rs17820875; section 2 (SNPs 60-115), rs10521303-rs8056199; and section 3 (SNPs 110-171), rs16952730-rs16953089].
PECS Results
Among PECS controls, carrying an increased number of copies of the minor A allele of rs8050136 in FTO was associated with increased mean BMI (Kruskal-Wallis P = 0.015) but not with the prevalence of diabetes (χ 2 , P = 0.26). rs1111875 in HHEX was not associated with BMI (P = 0.16) or diabetes (P = 0.56). In the PECS case-control analyses, the minor A allele of rs8050136 was not associated with endometrial cancer risk (per allele OR, 1.05; 95% CI, 0.86-1.28; P = 0.64). However, 20 of the remaining 171 FTO tagSNPs were significantly associated with endometrial cancer risk (per allele P values ranged from 0.00068 to 0.027) and represented independent SNPs (n = 4) or clustered into three linkage disequilibrium blocks. Haplotype analyses identified strong signals (haplotype P < 10 
Replication Studies
In an attempt to replicate our findings for FTO SNP rs12927155 and HHEX SNP rs1111875, we approached three independent case-control studies of women of European ancestry (5,522 subjects; .0 (24.9)] and with the PECS. We excluded controls with a history of hysterectomy (including 249 for SEARCH, 95 for ANECS, and 1 for LES). The SEARCH samples were genotyped using TaqMan assays, ANECS and LES samples were genotyped using the Sequenom iPLEX platform.
Among these three studies, the pooled per allele ORs, adjusted for continuous age and study for FTO was rs12927155 (OR, 0.94; 95% CI, 0.83-1.06; P = 0.29) and for HHEX, it was rs1111875 (OR, 1.00; 95% CI, 0.92-1.10; P = 0.96; Table 1 ). Between-study heterogeneity was not evident among these studies (P = 0.23 and 0.74, respectively), and the CIs for both SNPs excluded the ORs from the PECS.
Conclusion
Our data indicate that common genetic variants in two genes previously related to obesity (FTO) and diabetes (HHEX) by genome-wide association scans were not associated with endometrial cancer risk.
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